July 2020

AbbVie announces Positive Phase 3 Data for Atogepant in Migraine Prevention

  • Posted on: 31 July 2020
  • By: PharmaTutor News

AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo, for all doses across the 12-week treatment period.